LYONS GARY A
SEC CIK 1123343 · EDGAR
BoughtSold
Most active insiders at TVTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Dube Eric M | CEO, Dir | — | $41.35M |
| 2 | Heerma Peter | EVP, Chief COMMERCIAL Off | — | $18.97M |
| 3 | ROTE WILLIAM E. | Chief Research Off | — | $16.43M |
| 4 | REED ELIZABETH E | CLO, GC | — | $7.02M |
| 5 | Inrig Jula | EVP, CMO, Head of R, D | — | $5.16M |
| 6 | Cline Christopher R. | CFO | — | $4.64M |
| 7 | Calvin Sandra | SVP, CAO | — | $4.19M |
| 8 | Baynes Roy D. | Dir | — | $2.55M |
| 9 | Meckler Jeffrey A | Dir | — | $1.71M |
| 10 | Coughlin Timothy | Dir | — | $1.27M |
| 11 | LYONS GARY A | Dir | — | $961.4K |
Transactions 37
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-19 16:05 | 2026-08-17+ | TVTX | Travere Therapeutics, Inc. | LYONS GARY A | Dir | M - OptEx | $17.44 | +10.0K | 66.5K | +18% | +$174.4K |
| DMT | 2026-08-19 16:05 | 2026-08-17+ | TVTX | Travere Therapeutics, Inc. | LYONS GARY A | Dir | S - Sale+OE | $63.28 | -10.0K | 61.5K | -14% | -$632.8K |
| D | 2026-05-21 19:21 | 2026-05-21 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | M - OptEx | $0.00 | +1,659 | 122.1K | +1% | $0 |
| D | 2026-05-21 17:00 | 2026-05-19 | TVTX | Travere Therapeutics, Inc. | LYONS GARY A | Dir | A - Grant | $0.00 | +4,000 | 61.5K | +7% | $0 |
| DT | 2026-04-16 16:05 | 2026-04-14 | TVTX | Travere Therapeutics, Inc. | LYONS GARY A | Dir | M - OptEx | $16.33 | +8,000 | 65.5K | +14% | +$130.6K |
| DT | 2026-04-16 16:05 | 2026-04-14 | TVTX | Travere Therapeutics, Inc. | LYONS GARY A | Dir | S - Sale+OE | $41.07 | -8,000 | 57.5K | -12% | -$328.6K |
| D | 2025-12-04 | 2025-12-03 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | S - Sale+OE | $152.61 | -15.0K | 120.5K | -11% | -$2.29M |
| D | 2025-12-04 | 2025-12-03 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | M - OptEx | $47.89 | +15.0K | 135.5K | +12% | +$718.4K |
| D | 2025-05-22 | 2025-05-22 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | M - OptEx | $0.00 | +1,435 | 120.5K | +1% | $0 |
| D | 2025-05-16 | 2025-05-15 | TVTX | Travere Therapeutics, Inc. | LYONS GARY A | Dir | A - Grant | $0.00 | +6,500 | 57.5K | +13% | $0 |
| DM | 2024-10-04 | 2024-10-04 | TVTX | Travere Therapeutics, Inc. | LYONS GARY A | Dir | S - Sale+OE | $14.73 | -40.0K | 69.8K | -36% | -$589.1K |
| D | 2024-10-04 | 2024-10-04 | TVTX | Travere Therapeutics, Inc. | LYONS GARY A | Dir | M - OptEx | $10.48 | +40.0K | 91.0K | +78% | +$419.2K |
| D | 2024-08-15 | 2024-08-13 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | M - OptEx | $42.76 | +11.6K | 130.6K | +10% | +$494.7K |
| D | 2024-08-15 | 2024-08-13 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | S - Sale+OE | $150.43 | -11.6K | 119.0K | -9% | -$1.74M |
| D | 2024-07-18 | 2024-07-16 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | M - OptEx | $42.76 | +930 | 120.0K | +0.8% | +$39.8K |
| D | 2024-07-18 | 2024-07-16 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | S - Sale+OE | $150.03 | -930 | 119.0K | -0.8% | -$139.5K |
| D | 2024-05-21 | 2024-05-17 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | M - OptEx | $0.00 | +2,100 | 119.0K | +2% | $0 |
| D | 2024-05-16 | 2024-05-14 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | S - Sale+OE | $135.63 | -12.5K | 116.9K | -10% | -$1.70M |
| D | 2024-05-16 | 2024-05-14 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | M - OptEx | $42.76 | +12.5K | 129.4K | +11% | +$534.5K |
| D | 2024-05-10 | 2024-05-08 | TVTX | Travere Therapeutics, Inc. | LYONS GARY A | Dir | A - Grant | $0.00 | +6,500 | 51.0K | +15% | $0 |
| 2023-12-27 | 2023-12-22 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | S - Sale | $130.04 | -10.0K | 193.7K | -5% | -$1.30M | |
| D | 2023-12-05 | 2023-12-01 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | M - OptEx | $12.98 | +5,000 | 208.7K | +2% | +$64.9K |
| D | 2023-12-05 | 2023-12-01 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | S - Sale+OE | $116.77 | -5,000 | 203.7K | -2% | -$583.9K |
| D | 2023-09-14 | 2023-09-12 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | S - Sale+OE | $115.02 | -5,000 | 203.7K | -2% | -$575.1K |
| D | 2023-09-14 | 2023-09-12 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | M - OptEx | $12.98 | +5,000 | 208.7K | +2% | +$64.9K |
| D | 2023-09-06 | 2023-09-01 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | S - Sale+OE | $110.06 | -5,000 | 203.7K | -2% | -$550.3K |
| D | 2023-09-06 | 2023-09-01 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | M - OptEx | $12.98 | +5,000 | 208.7K | +2% | +$64.9K |
| D | 2023-07-12 | 2023-05-26 | RIGL | RIGEL PHARMACEUTICALS INC | LYONS GARY A | Dir | A - Grant | $0.00 | +25.0K | 75.0K | +50% | $0 |
| D | 2023-05-19 | 2023-05-17 | TVTX | Travere Therapeutics, Inc. | LYONS GARY A | Dir | A - Grant | $0.00 | +4,500 | 44.5K | +11% | $0 |
| D | 2022-11-02 | 2022-10-31 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | M - OptEx | $12.71 | +15.0K | 218.7K | +7% | +$190.7K |
| D | 2022-11-02 | 2022-10-31 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | S - Sale+OE | $114.76 | -15.0K | 203.7K | -7% | -$1.72M |
| 2022-10-05 | 2022-10-04 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | S - Sale | $110.54 | -5,000 | 203.7K | -2% | -$552.7K | |
| D | 2022-05-23 | 2022-05-20 | RIGL | RIGEL PHARMACEUTICALS INC | LYONS GARY A | Dir | A - Grant | $0.00 | +25.0K | 50.0K | +100% | $0 |
| D | 2022-05-12 | 2022-05-11 | TVTX | Travere Therapeutics, Inc. | LYONS GARY A | Dir | A - Grant | $0.00 | +3,000 | 40.0K | +8% | $0 |
| D | 2022-04-27 | 2022-04-25 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | S - Sale+OE | $92.76 | -15.0K | 208.7K | -7% | -$1.39M |
| D | 2022-04-27 | 2022-04-25 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | M - OptEx | $6.66 | +15.0K | 223.7K | +7% | +$99.9K |
| 2021-10-12 | 2021-10-07 | NBIX | NEUROCRINE BIOSCIENCES INC | LYONS GARY A | Dir | S - Sale | $105.06 | -5,000 | 208.7K | -2% | -$525.3K |
Purchase Sale Sale after option exercise All abbreviations